Journey Medical (NASDAQ:DERM) Releases Quarterly Earnings Results, Misses Estimates By $0.03 EPS

Journey Medical (NASDAQ:DERM) issued its quarterly earnings results on Monday. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.03), Yahoo Finance reports. Journey Medical had a negative return on equity of 32.83% and a negative net margin of 5.20%. The business had revenue of $14.86 million for the quarter, compared to analyst estimates of $13.81 million. During the same quarter in the prior year, the firm earned ($0.46) EPS.

Journey Medical Stock Down 9.3 %

NASDAQ DERM traded down $0.45 during trading on Wednesday, reaching $4.37. 25,626 shares of the stock traded hands, compared to its average volume of 134,955. Journey Medical has a fifty-two week low of $1.78 and a fifty-two week high of $8.11. The company has a current ratio of 1.21, a quick ratio of 0.94 and a debt-to-equity ratio of 1.13. The company has a market capitalization of $87.46 million, a price-to-earnings ratio of -15.55 and a beta of 0.93. The firm’s 50-day moving average is $5.31.

Analysts Set New Price Targets

DERM has been the subject of a number of analyst reports. Roth Mkm assumed coverage on shares of Journey Medical in a report on Friday, June 28th. They set a “buy” rating and a $11.00 target price for the company. Roth Capital upgraded Journey Medical to a “strong-buy” rating in a research report on Friday, June 28th.

Insiders Place Their Bets

In other news, CFO Joseph Benesch sold 9,324 shares of the business’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $5.47, for a total value of $51,002.28. Following the completion of the transaction, the chief financial officer now owns 47,331 shares of the company’s stock, valued at approximately $258,900.57. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 19.42% of the company’s stock.

About Journey Medical

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.